All News

cush.tkr_.jpg

TKR - One or Two at a Time?

d RheumNow

His would-be surgeon tried mightily to talk him out of a bilateral knee replacement. At 340 pounds, the patient's BMI -- above 43 -- was a significant contraindication. 

Read Article
bone%20dense.jpg (keep)

Older Men Less Likely to be Assessed and Treated for Osteoporosis

d Jack Cush, MD

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Read Article
hip.THR_.jpg

Hip Replacements Lasting 25 Years

d Jack Cush, MD

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

Read Article
Review of IL-21 - made by follicular helper T & Th17 cells; promotes B cell maturation/function, mediated thru activation of the JAK/STAT, MAPK, PI3K pathways. IL-21 is increased in autoimmune patients - may be Rx target in RA, SLE, RA, T1D, PsA https://t.co/ld1Q3fHw9N

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of 541,744 total knee replacement (TKR) in Australia (1999-2017) finds lower revision rates in RA vs. OA, but increased risk of infection in RA (esp. males) https://t.co/rIpSFWSNfY

Links:

Dr. John Cush RheumNow ( View Tweet)

Finnish population study of 4180 JIA patients shows JIA mortality not increased (0.6%) vs Nl population. Mmean age at death 20.3 yrs; Most common JIA cause was accidents, vs. suicide in controls. JIA pts had less substance abuse and depression https://t.co/9WiJJPxChR

Links:

Dr. John Cush RheumNow ( View Tweet)

Lancet study of 10166 chronic Hepatitis C patients shows treatment with direct-acting antivirals was associated with a 52% decrease in all-cause mortality (adjusted HR 0·48) and a 34% decrease in hepatocellular carcinoma (0·66) https://t.co/62HylUMUwE

Links:

Dr. John Cush RheumNow ( View Tweet)

Listen to the speakers from last weeks RWCS 2019 Podcast from Maui- https://t.co/hA1A0CHCz0

Links:

Dr. John Cush RheumNow ( View Tweet)

More than half (53%) of hospital deaths are from sepsis and sepsis is the most common immediate cause of death (35%) according to a medical record review from 6 academic centers https://t.co/Sp5rFTbg3m

Links:

Dr. John Cush RheumNow ( View Tweet)

"In order to solve a problem, you need to sell it first.....remarket your problem with a story that resonates." - Seth Godin  https://t.co/HHF9eMV7sk

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Orrin Troum shows data on ANA negative pts. Should this include those with cytoplasmic staining? #RWCS2019 https://t.co/EDV882CQ9E
Dr. John Cush RheumNow ( View Tweet)
Dr Orrin Troum shows that TB Tspot is more sensitive than QFT in school of TB. But no specificity data. #RWCS2019 https://t.co/KJ2i0EKim3
Dr. John Cush RheumNow ( View Tweet)
The RheumNow Weekly Podcast is up! Info on SEAM-PsA, SEAM trial, MRI T2T, biologics & infection, contraceptive use, ANA negative lupus. View here>> https://t.co/tv2ANE0LAp or listen on iTunes or SoundClound https://t.co/uXZEI1jmkJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Anne Stevens. Other arc options for localized scleroderma include tocilizumab and abatacept. #RWCS2019 https://t.co/AIfARTZ3CD
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens shows that CARRA pediatric rheums treat localized scleroderma with steroids and MTX #RWCS2019 https://t.co/h9s5Owz8J3
Dr. John Cush RheumNow ( View Tweet)
Dr Anne Stevens compare localized and diffuse pediatric scleroderma #RWCS2019 https://t.co/KJLGHlvqiE
Dr. John Cush RheumNow ( View Tweet)
FREEDOM trial 3,591 postmenop. women Rx w/ denosumab vs PBO x3 years - No difference in dental procedures (~45%), adjudicated osteonecrosis of jaw (13 cases) - risk was 0.68% vs. 0.05% w/ and withour invasive oral procedures. https://t.co/dxWuzEjUnk

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Eric Ruderman shows that filgotinib (Jak inhibitor) maybe effect in ankylosing spondylitis. #RWCS2019 https://t.co/0km5vMHFpQ
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman shows data on the lack of effect with ustrkinumab in biological naive ankylosing spondylitis. #RWCS2019 https://t.co/Wqx7Us1Qrl
Dr. John Cush RheumNow ( View Tweet)
Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019 https://t.co/dk7orkumEd
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×